Parodontális vertikális csontdefektusok gyógyulásának hosszú távú kiértékelése PRG- vagy EMD-vel történt kezelést követően

A retrospektív esetsorozat célja intraosszeális csontdefektusok gyógyulásának hosszú távú klinikai értékelése autológ vérlemezkében gazdag készítménnyel (Platelet-Rich Gel, PRG) vagy zománc-mátrix derivátummal (Enamel Matrix Derivatives, EMD) történt kezelést követően.A vizsgálatban 24 intraosszeális defektussal rendelkező, nem dohányzó, krónikus parodontitisben szenvedő páciens vett részt. A négy bemutatott eset ezen kontrollált klinikai vizsgálat résztvevője, akiknél 1, 3, illetve 7 évvel a műtétet követően történt kiértékelés a következő paraméterek rögzítésével: szondázási mélység (PD – probing depth), illetve klinikai tapadási szint (CAL – clinical attachment level). Teljes vastagságú lebenyek képzését követően a defektus kürettálása, illetve gyökérsimítás történt. Vérlemezkében gazdag plazma (PRP) preparálása után, Ca-glükonát és friss vénás vér hozzáadásával vérlemezkében gazdag plazma gél (PRG) készült. A parodontális vertikális defektusok ellátását PRG(n = 2) vagy EMD (n = 2) applikációját követően sebzárás követte.Egy évvel a műtét után mindkét kezelési módszer szignifikáns szondázási mélység (PD) csökkenést és klinikai tapadási nívó (CAL) növekedést eredményezett, és ezek az eredmények 3, illetve 7 év után is kedvezőek maradtak. Bemutatott eseteinknél, úgy a PRG-, mint az EMD-kezelés megbízható hosszú távú klinikai eredményeket mutatott.

EXPERIENCE OF USING ENAMEL MATRIX PROTEIN IN COMBINATION WITH A CORONARY ADVANCED FLAP AND A CONNECTIVE TISSUE GRAFT TO ELIMINATE GUM RECESSION

The article presents the experience of complex managing a patient with gum recession in the area of the maxillary premolars. Periodontal treatment of gum recession consisted of initial therapy, including supra- and subgingival scaling, root planing, pharmacotherapeutic support (broad-spectrum antiseptics, drugs that stimulate regeneration), surgical combined method based on the use of enamel matrix protein to stimulate regenerative processes. The clinical material Emdogaine is a combination of an enamel matrix derivative and propylene glycol alginate, which performs the function of a carrier. Biora company has been producing it for more than 20 years (Emdogain, BIORA): now the rights to this material belong to Straumann). This preparation was developed to stimulate regeneration of periodontal tissues. Amelogenin is a specific enamel protein capable of stimulating regeneration of lost periodontal tissues by influencing cell differentiation. Dental cement is an osteoid connective tissue that covers the roots of teeth and serves to attach periodontal fibers. Application of an enamel matrix derivative to the sanitized root surface leads to regeneration of non-cellular cement and to the formation of periodontal tissues, which was observed in our study. Transplantation of free connective tissue grafts to eliminate gum recessions makes it possible to effectively eliminate gum recession in most clinical cases (complete root coverage, an increase in the level of clinical attachment from the keratinized attached gum area). In our clinical case, free grafts were obtained in the donor area of the maxillary tuberosity. Transplantation of free connective tissue grafts provides an aesthetic result and is currently considered a standard technique for eliminating gum recession. According to the clinical study, a combined use of connective tissue grafts and the enamel matrix derivative, an additional use of enamel matrix derivative enabled to obtain a satisfactory result and to improve the appearance of the dentition. Such combined surgeries are indicated in an aesthetically significant area. The described materials, methods and stages of patient's follow up can serve as the basis for the protocol of managing patients with gum recession.

Apical approach in periodontal reconstructive surgery with enamel matrix derivate and enamel matrix derivate plus bone substitutes: a randomized, controlled clinical trial

Objectives This parallel, randomized controlled clinical trial evaluated the influence of bone substitutes (BS) on the efficacy of the non-incised papillae surgical approach (NIPSA) with enamel matrix derivate (EMD) in resolving deep, isolated, combined non-contained intrabony and supra-alveolar periodontal defects, preserving the soft tissue. Material and methods Twenty-four patients were randomized to treatment with NIPSA and EMD or NIPSA plus EMD and BS. Bleeding on probing (BoP), interproximal clinical attachment level (CAL), interproximal probing depth (PD), recession (REC), location of the tip of the papilla (TP), and width of the keratinized tissue (KT) were evaluated before surgery and at 1 year post-surgery (primary outcomes). Wound closure was assessed at 1 week post‐surgery, and supra‐alveolar attachment gain (SUPRA-AG) was recorded at 1 year post‐surgery. Results At 1 week, 87.5% of cases registered complete wound closure and there were no cases of necrosis, without differences between groups (p > .05). At 1 year, all cases showed negative BoP. A significant PD reduction (NIPSA + EMD 8.25 ± 2.70 mm vs. NIPSA + EMD + BS 6.83 ± 0.81 mm) and CAL gain (NIPSA + EMD 8.33 ± 2.74 mm vs. NIPSA + EMD + BS 7.08 ± 2.68 mm) were observed (p < .001) in both groups, without significant between-group differences (p > .05). The residual PD was < 5 mm in all defects (NIPSA + EMD 2.50 ± 0.67 mm vs. NIPSA + EMD + BS 2.67 ± 0.78 mm). Soft tissues were preserved without significant between-group differences (REC: NIPSA + EMD 0.25 ± 0.45 mm vs. NIPSA + EMD + BS 0.17 ± 0.58 mm, p > .05; KT: 0.00 ± 0.43 mm vs. 0.08 ± 0.67 mm, p > .05). There were improvements in the papilla in both groups (TP: NIPSA + EMD 0.33 ± 0.49 mm vs. NIPSA + EMD + BS 0.45 ± 0.52 mm, p > .05), which was only significant in the NIPSA EMD + BS group (0.45 ± 0.52 mm; p < .05). In both groups, CAL gain was recorded in the supra-alveolar component, showing full resolution of the intrabony component of the defect in all cases (SUPRA-AG: NIPSA + EMD 1.83 ± 1.11 mm vs. NIPSA + EMD + BS 2.00 ± 1.76 mm, p > .05). Conclusions NIPSA and EMD with or without BS seem to be a valid surgical approach in the treatment of isolated, deep non-contained periodontal defects. In our study, both treatments resulted in significant PD reduction and CAL gain, that extended in the supra-alveolar component, without differences with the use of BS. Both treatments resulted in soft tissue preservation. However, the addition of BS may improve interdental papillary tissue. Clinical relevance NIPSA, with or without bone substitutes, resulted in significant periodontal improvement, with soft tissue preservation in isolated, deep non-contained periodontal defects. The application of bone substitutes may provide interproximal soft tissue gain. Clinical trial registration Clinicaltrials.gov: NCT04712630.

Low Frequency Electromagnetic Fields Might Increase the Effect of Enamel Matrix Derivative on Periodontal Tissues

Periodontal regeneration is a complex goal, which is commonly pursued with a combination of surgical techniques, biomaterials, and bioactive compounds. One such compound is enamel matrix derivative (EMD), a medical substance that is extracted from porcine tooth germs and which contains several protein fractions with BMP- and TGF-β-like action. Activation of TGF-β signaling is required for EMD activity on cells and tissues, and a growing body of evidence indicates that EMD largely relies on this pathway. As low frequency electromagnetic fields (EMFs) have long been investigated as a tool to promote bone formation and osteoblast activity, and because recent studies have reported that the effects of EMFs on cells require primary cilia, by modulating the presence of membrane-bound receptors (e.g., for BMP) or signal mediators, it can be hypothesized that the application of EMFs may increase cell sensitivity to EMD: as TGFBR receptors have also been identified on primary cilia, EMFs could make cells more responsive to EMD by inducing the display of a higher number of receptors on the cellular membrane.

A associação do enxerto de tecido conjuntivo subepitelial e a matriz derivada do esmalte no recobrimento das recessões gengivais

A recessão gengival (RG) pode ser definida como uma condição, na qual ocorre a migração em sentido apical com consequente exposição da junção amelo-cementária e superfície radicular. As técnicas cirúrgicas plásticas periodontais objetivam a melhora do fenótipo gengival e a correção da morfologia, posição e dimensões do tecido gengival. Nos últimos anos, com o intuito de melhorar os resultados destes tratamentos, novos recursos relacionados com a otimização da regeneração periodontal, vem sendo associados aos enxertos gengivais. Sendo um coadjuvante ou não às técnicas cirúrgicas de recobrimento radicular, a matriz derivada do esmalte (Emdogain â), tem sido cada vez mais incorporada nesses tratamentos, na medida em que, tanto sua aplicabilidade clínica, como seus benefícios, já se encontra embasados em evidências científicas. O objetivo deste estudo é realizar uma revisão literária integrativa sobre a utilização da matriz derivada do esmalte (EMD) nos procedimentos cirúrgicos plásticos periodontais para o tratamento da recessão gengival. Para a elaboração do estudo foi utilizada a estratégia PICO e a busca nas bases de dados PubMed, MedLine e Scielo, a partir das seguintes palavras-chave: “enamel matrix derivatives”, “gingival retraction” e “subepithelial connective tissue graft”. A partir dessa busca 181 artigos publicados entre os anos de 2016 a 2021 foram selecionados, sendo que desse número, somente 12 foram utilizados para realizar a revisão da literatura. Com esta revisão foi possível concluir que a EMD associada aos enxertos de tecido conjuntivo subepitelial pode aumentar a previsibilidade da terapia de recobrimento, podendo favorecer uma nova inserção periodontal.

The Outcomes of Enamel Matrix Derivative on Periodontal Regeneration under Diabetic Conditions

Background and Objectives: Enamel matrix derivative (EMD) is a biomaterial used for periodontal regenerative therapy due to its properties of stimulating cementum development and bone synthesis. Diabetes is a chronic condition that affects healing and predisposes to infection. The aim of this review was to evaluate the current studies available on the application and results of EMD for periodontal regenerative therapy under diabetic conditions. Materials and Methods: Five databases (PubMed, ResearchGate, Scopus, Web of Science and Google Scholar) were searched for relevant articles, using specific keywords in different combinations. The inclusion criteria were clinical trials, case reports, case studies, and animal studies published in English, where periodontal treatment for bone defects includes EMD, and it is performed under diabetic conditions. Results: Of the 310 articles resulted in search, five studies published between 2012 and 2020 met the inclusion criteria and were selected for the current review. In human studies, the use of EMD in infrabony defects showed favorable results at follow-up. In animal studies, periodontal regeneration was reduced in diabetic rats. Conclusions: EMD might promote bone healing when used under diabetic conditions for the regenerative periodontal therapy. Due to limited number of studies, more data are required to sustain the effects of EMD therapy in diabetic settings.